# Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

> **NCT02113397** · — · TERMINATED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** TOBI™ Podhaler™ 112 mg inhaled twice daily
- **DRUG:** Colistimethate 75 mg inhaled two times daily

## Key facts

- **NCT ID:** NCT02113397
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2018-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113397, "Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02113397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*